Lucis

What do they actually do

Lucis runs a preventive‑health service in Europe built around clinic‑grade blood tests. Customers book a draw at a partner lab, the lab analyzes dozens to 100+ biomarkers, and Lucis turns the results into simple health scores, a biological‑age estimate, and a prioritized plan (nutrition, sleep, movement, supplements). Their software generates the guidance and a clinical team reviews it before delivery; optional add‑ons like microbiome and CGM are available, and repeat checks track progress over time (YC company profile/launch, Work at a Startup, YC launch post).

They sell direct‑to‑consumer and as an employee benefit, and operate through integrations with national lab networks across multiple cities (they cite traction in Paris and launches in Lisbon and London). They emphasize data privacy/compliance and faster report turnaround, and have publicly signaled pricing around €490 per year for a package (YC company profile, Work at a Startup, LinkedIn company page).

Who are their target customer(s)

• Urban, health‑conscious adults seeking preventive care: They don’t know which labs to order or how to interpret raw results, and want simple, prioritized steps they can follow instead of numbers without context.
• Small‑to‑mid startups buying employee benefits: They need an affordable health perk that employees actually use and value, and struggle to justify perks that don’t improve wellness or engagement.
• People with borderline or confusing lab results: They’re told results are “normal” without actionable guidance, and want a clear, clinician‑reviewed plan that prioritizes what to do next.
• Users of consumer health apps wary of generic AI: They distrust non‑validated advice and worry about data privacy; they want recommendations grounded in clinical review with strong data handling practices.
• City residents wanting clinic‑grade testing without specialty visits: Local options can be limited and slow, with opaque turnaround; they want convenient draws at standard labs and clear, timely reports.

How would they acquire their first 10, 50, and 100 customers

• First 10: Personal outreach and white‑glove pilots with friends, YC/startup contacts and local clinicians; book their draws manually, review results with clinicians, and collect testimonials to build trust.
• First 50: Run 2–3 employer pilots (bulk bookings via invoice/portal) and host weekend pop‑up draw days at partner labs to convert walk‑ins; gather structured feedback and short case studies, with referral incentives to turn pilots into recurring deals.
• First 100: Standardize the employer sales playbook (LinkedIn outreach, one‑pager, onboarding checklist), run pop‑ups on a cadence, and publish anonymized sample reports and “how to act on your labs” guides; automate booking/report workflows and A/B test pricing and add‑ons to reduce acquisition effort.

What is the rough total addressable market

Top-down context:

The broader European in‑vitro diagnostics market is on the order of ~$23B in 2024 and growing, but most spend is hospital/GP‑driven; Lucis targets the smaller, consumer and employer‑paid slice focused on preventive blood testing plus interpretation (Yahoo Finance summary, MedTech Europe reference).

Bottom-up calculation:

The Europe direct‑to‑consumer lab testing market is estimated around ~$0.78–1.6B in the mid‑2020s; at a headline price near €490/year, that supports several hundred thousand to a few million annual purchases, with employer contracts multiplying volume through bulk buying (MarketDataForecast, Meticulous Research, LinkedIn pricing signal).

Assumptions:

• Average revenue per user ~€490/year for a core package.
• Tests are purchased annually (or on a similar cadence) by most active users.
• Employer contracts purchase comparable per‑employee packages and can drive higher uptake in cities where lab coverage exists.

Who are some of their notable competitors

• Thriva: UK consumer blood testing with at‑home kits and clinic options plus app and doctor commentary; strong in UK direct‑to‑consumer logistics, less focused on a Europe‑wide AI+clinician navigator.
• Medichecks: Online lab‑order service selling venous/finger‑prick panels with clinician notes and fast turnaround; overlaps on consumer testing but is primarily a diagnostics ordering platform rather than a health‑navigation layer.
• InsideTracker: US‑origin platform that converts blood (plus DNA/wearables) into biological‑age and action plans; closer feature match on interpretation, but blood‑draw operations are US/Canada‑centric for now.
• Baze: Personalized supplements based on at‑home nutrient testing; competes where micronutrient guidance matters, but commercial focus is supplement delivery rather than broad biomarker navigation or B2B benefits.
• Randox Health: Established diagnostics and private clinics offering comprehensive biomarker panels, interpreted reports and corporate health checks; positioned as a premium clinic/pathology brand rather than a consumer‑first AI navigator.